You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

633 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Dec 2020
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Lymphoma - T-cell
Intent: Curative
Feb 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Drugs Used:
pentostatin (Unfunded),
alemtuzumab (Compassionate)
Apr 2021

Pages